Switch to:
Also traded in: Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.18
BAYRY's Cash-to-Debt is ranked lower than
86% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. BAYRY: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
BAYRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.29 Max: No Debt
Current: 0.18
Equity-to-Asset 0.31
BAYRY's Equity-to-Asset is ranked lower than
88% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BAYRY: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
BAYRY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: 0.46
Current: 0.31
0.21
0.46
Interest Coverage 7.15
BAYRY's Interest Coverage is ranked lower than
77% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. BAYRY: 7.15 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.57  Med: 5.71 Max: N/A
Current: 7.15
Piotroski F-Score: 7
Altman Z-Score: 2.03
Beneish M-Score: -2.61
WACC vs ROIC
7.28%
10.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 11.95
BAYRY's Operating Margin % is ranked higher than
61% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.64 vs. BAYRY: 11.95 )
Ranked among companies with meaningful Operating Margin % only.
BAYRY' s Operating Margin % Range Over the Past 10 Years
Min: 7.78  Med: 10.11 Max: 11.95
Current: 11.95
7.78
11.95
Net Margin % 10.08
BAYRY's Net Margin % is ranked higher than
64% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.21 vs. BAYRY: 10.08 )
Ranked among companies with meaningful Net Margin % only.
BAYRY' s Net Margin % Range Over the Past 10 Years
Min: 3.71  Med: 6.41 Max: 14.55
Current: 10.08
3.71
14.55
ROE % 20.14
BAYRY's ROE % is ranked higher than
82% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.92 vs. BAYRY: 20.14 )
Ranked among companies with meaningful ROE % only.
BAYRY' s ROE % Range Over the Past 10 Years
Min: 6.9  Med: 13.68 Max: 31.94
Current: 20.14
6.9
31.94
ROA % 6.22
BAYRY's ROA % is ranked higher than
65% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. BAYRY: 6.22 )
Ranked among companies with meaningful ROA % only.
BAYRY' s ROA % Range Over the Past 10 Years
Min: 2.54  Med: 4.68 Max: 8.78
Current: 6.22
2.54
8.78
ROC (Joel Greenblatt) % 32.88
BAYRY's ROC (Joel Greenblatt) % is ranked higher than
75% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. BAYRY: 32.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BAYRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.91  Med: 25.65 Max: 33.37
Current: 32.88
17.91
33.37
3-Year Revenue Growth Rate 5.20
BAYRY's 3-Year Revenue Growth Rate is ranked lower than
51% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. BAYRY: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BAYRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 2.6 Max: 11.1
Current: 5.2
-10.6
11.1
3-Year EBITDA Growth Rate 14.90
BAYRY's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. BAYRY: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BAYRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.9  Med: 3.2 Max: 15.4
Current: 14.9
-9.9
15.4
3-Year EPS without NRI Growth Rate 18.70
BAYRY's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.30 vs. BAYRY: 18.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BAYRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.1  Med: 8.9 Max: 39.3
Current: 18.7
-19.1
39.3
GuruFocus has detected 5 Warning Signs with Bayer AG $BAYRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BAYRY Guru Trades in Q1 2016

Ken Fisher 4,833,445 sh (+2.63%)
» More
Q2 2016

BAYRY Guru Trades in Q2 2016

Ken Fisher 4,909,612 sh (+1.58%)
» More
Q3 2016

BAYRY Guru Trades in Q3 2016

Ken Fisher 4,927,034 sh (+0.35%)
» More
Q4 2016

BAYRY Guru Trades in Q4 2016

Ken Fisher 4,859,655 sh (-1.37%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:BMY, NYSE:LLY, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, NYSE:MRK, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:NVSEF, OTCPK:PTKFY, OTCPK:GWPRF, NAS:HCM, OTCPK:MAYNF » details
Traded in other countries:BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Bayer AG is a research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences and crop sciences.

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.

Top Ranked Articles about Bayer AG

Monsanto Posts Profitable Quarter From South American Growth Company’s merger with Bayer remains on track
Monsanto Co. (NYSE:MON) posted strong first-quarter results for fiscal 2017 on Thursday, returning to profitability after battling a multiyear decline in the prices of corn, soybeans and other major crops. Read more...
Warren Buffett's Financial Engineering For decades Buffett used borrowed money and this strategy to crush the market
Investors often overlook the financial engineering that Warren Buffett (Trades, Portfolio) has employed throughout the years that helped build his personal fortune and the book value of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B). Read more...
Will the Monsanto-Bayer Deal Go Through? There are too many groups opposed to the merger
Bayer (BAYRY) has offered to buy Monsanto (NYSE:MON) for $128 a share, yet the market value of Monsanto is only $102.48. Evidently, the market does not think this deal is going to go through. Neither do I. Read more...
Monsanto Agrees to Bayer’s Proposal Merger would be largest foreign takeover by a German company
A proposed deal from Bayer (BAYRY) to buy Monsanto (NYSE:MON) was approved Wednesday. The deal will consolidate two of the world’s six agricultural giants. Read more...
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Analyzing the buying and selling of Monsanto shares to determine what 5 gurus expect from Bayer’s attempts to buy company
This week or next, a proposed deal in which Bayer AG (BAYRY) would buy the Monsanto Company (NYSE:MON) is expected to get the nod or get the boot. Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.40
BAYRY's PE Ratio is ranked higher than
70% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. BAYRY: 18.40 )
Ranked among companies with meaningful PE Ratio only.
BAYRY' s PE Ratio Range Over the Past 10 Years
Min: 8.01  Med: 22.7 Max: 38.59
Current: 18.4
8.01
38.59
Forward PE Ratio 13.16
BAYRY's Forward PE Ratio is ranked higher than
62% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. BAYRY: 13.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.01
BAYRY's PE Ratio without NRI is ranked higher than
70% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. BAYRY: 19.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAYRY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.77  Med: 23.47 Max: 38.59
Current: 19.01
14.77
38.59
Price-to-Owner-Earnings 18.39
BAYRY's Price-to-Owner-Earnings is ranked higher than
72% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. BAYRY: 18.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAYRY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.35  Med: 16.14 Max: 31.13
Current: 18.39
7.35
31.13
PB Ratio 3.69
BAYRY's PB Ratio is ranked lower than
61% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. BAYRY: 3.69 )
Ranked among companies with meaningful PB Ratio only.
BAYRY' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 2.59 Max: 5.55
Current: 3.69
1.54
5.55
PS Ratio 1.84
BAYRY's PS Ratio is ranked higher than
66% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. BAYRY: 1.84 )
Ranked among companies with meaningful PS Ratio only.
BAYRY' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.38 Max: 2.82
Current: 1.84
0.87
2.82
Price-to-Free-Cash-Flow 15.08
BAYRY's Price-to-Free-Cash-Flow is ranked higher than
71% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. BAYRY: 15.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAYRY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.27  Med: 19.53 Max: 248.88
Current: 15.08
7.27
248.88
Price-to-Operating-Cash-Flow 10.49
BAYRY's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. BAYRY: 10.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAYRY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.51  Med: 9.86 Max: 19.39
Current: 10.49
5.51
19.39
EV-to-EBIT 15.68
BAYRY's EV-to-EBIT is ranked higher than
64% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. BAYRY: 15.68 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 17.3 Max: 29.4
Current: 15.68
7.8
29.4
EV-to-EBITDA 10.16
BAYRY's EV-to-EBITDA is ranked higher than
75% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. BAYRY: 10.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 9.8 Max: 17.9
Current: 10.16
4.4
17.9
PEG Ratio 2.55
BAYRY's PEG Ratio is ranked lower than
63% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. BAYRY: 2.55 )
Ranked among companies with meaningful PEG Ratio only.
BAYRY' s PEG Ratio Range Over the Past 10 Years
Min: 1.14  Med: 3.38 Max: 469.75
Current: 2.55
1.14
469.75
Shiller PE Ratio 27.97
BAYRY's Shiller PE Ratio is ranked higher than
71% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 47.37 vs. BAYRY: 27.97 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAYRY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.74  Med: 28.74 Max: 42.5
Current: 27.97
16.74
42.5
Current Ratio 1.51
BAYRY's Current Ratio is ranked lower than
72% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. BAYRY: 1.51 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.51 Max: 2.13
Current: 1.51
1
2.13
Quick Ratio 1.01
BAYRY's Quick Ratio is ranked lower than
76% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. BAYRY: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.01 Max: 1.44
Current: 1.01
0.64
1.44
Days Inventory 151.50
BAYRY's Days Inventory is ranked lower than
67% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. BAYRY: 151.50 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.65  Med: 138.65 Max: 154.01
Current: 151.5
126.65
154.01
Days Sales Outstanding 84.37
BAYRY's Days Sales Outstanding is ranked lower than
57% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. BAYRY: 84.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.71  Med: 69.96 Max: 84.37
Current: 84.37
65.71
84.37
Days Payable 87.98
BAYRY's Days Payable is ranked higher than
64% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. BAYRY: 87.98 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 75.75 Max: 102.56
Current: 87.98
54.65
102.56

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.59
BAYRY's Dividend Yield % is ranked higher than
69% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. BAYRY: 2.59 )
Ranked among companies with meaningful Dividend Yield % only.
BAYRY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.44  Med: 2.39 Max: 3.93
Current: 2.59
1.44
3.93
Dividend Payout Ratio 0.46
BAYRY's Dividend Payout Ratio is ranked lower than
61% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. BAYRY: 0.46 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAYRY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.51 Max: 0.89
Current: 0.46
0.36
0.89
3-Year Dividend Growth Rate 10.90
BAYRY's 3-Year Dividend Growth Rate is ranked higher than
55% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. BAYRY: 10.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAYRY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.6 Max: 34.9
Current: 10.9
0
34.9
Forward Dividend Yield % 2.59
BAYRY's Forward Dividend Yield % is ranked higher than
67% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. BAYRY: 2.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.27
BAYRY's 5-Year Yield-on-Cost % is ranked higher than
78% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. BAYRY: 4.27 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAYRY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.38  Med: 3.96 Max: 6.5
Current: 4.27
2.38
6.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.56
BAYRY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. BAYRY: 1.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAYRY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.77 Max: 4.09
Current: 1.56
0.8
4.09
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.34
BAYRY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
51% of the 78 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. BAYRY: 1.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.34
BAYRY's Price-to-Median-PS-Value is ranked lower than
64% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. BAYRY: 1.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAYRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.89 Max: 1.95
Current: 1.34
0.23
1.95
Price-to-Peter-Lynch-Fair-Value 1.76
BAYRY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
59% of the 168 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. BAYRY: 1.76 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BAYRY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.7  Med: 2.17 Max: 5.7
Current: 1.76
0.7
5.7
Earnings Yield (Greenblatt) % 6.42
BAYRY's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. BAYRY: 6.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAYRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 5.8 Max: 12.9
Current: 6.42
3.4
12.9
Forward Rate of Return (Yacktman) % 15.10
BAYRY's Forward Rate of Return (Yacktman) % is ranked higher than
61% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. BAYRY: 15.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAYRY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.4  Med: 9.1 Max: 26.4
Current: 15.1
-11.4
26.4

More Statistics

Revenue (TTM) (Mil) $51,786
EPS (TTM) $ 6.33
Beta1.09
Short Percentage of Float0.01%
52-Week Range $91.53 - 125.20
Shares Outstanding (Mil)826.95

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 49,206 51,434 53,918
EPS ($) 7.86 8.39 8.93
EPS without NRI ($) 7.86 8.39 8.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.99%
Dividends per Share ($) 2.72 2.88 3.23
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
2 Arbitrage Ideas From Warren Buffett and Seth Klarman Feb 23 2017 
A Green Light on Bayer Jan 19 2017 
Monsanto Posts Profitable Quarter From South American Growth Jan 06 2017 
A Year in Review and Recommendations for 2017 Dec 27 2016 
Warren Buffett's Financial Engineering Nov 15 2016 
3 Chemical Companies From Polaris Global Value Oct 17 2016 
Will the Monsanto-Bayer Deal Go Through? Sep 20 2016 
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Monsanto Agrees to Bayer’s Proposal Sep 15 2016 
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Sep 13 2016 

More From Other Websites
Prior job cuts lead to surplus of space, which Bayer now hopes to fill with startups Feb 24 2017
[$$] Fusion Pharmaceuticals Raises $25 Million for Targeted Cancer Therapies Feb 23 2017
2 Arbitrage Ideas From Warren Buffett and Seth Klarman Feb 23 2017
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line Feb 23 2017
[$$] Bayer CEO Confident Monsanto Purchase Will Be Approved by End of Year Feb 23 2017
[$$] Bayer Details Financing Plan for Monsanto Deal Feb 23 2017
Bayer Offers Further Detail on Financing Monsanto Takeover Feb 22 2017
[$$] Bayer Details Financing Plan for Monsanto Deal Feb 22 2017
Bayer says Monsanto deal on track, eyes record 2017 Feb 22 2017
Bayer sees pesticides profits stagnating before Monsanto takeover Feb 22 2017
Bayer sees pesticides profits stagnating before Monsanto takeover Feb 22 2017
Bayer sees pesticides profits stagnating before Monsanto takeover Feb 22 2017
Bayer sees pesticides profits stagnating before Monsanto takeover Feb 22 2017
[$$] Bayer CEO Confident Monsanto Purchase Will Be Approved by End of Year Feb 22 2017
European Stocks Extend Gains as Economic Data Continues to Impress Feb 22 2017
Bayer Shares Drop After Cautious 2017 Outlook For Crop Science Unit Feb 22 2017
[$$] Strong pharmaceuticals earnings boost profits at Bayer Feb 22 2017
Bayer Hints at Delay on Monsanto as Regulators Seek Details Feb 22 2017
Bayer says Monsanto deal on track, eyes record 2017 Feb 21 2017
Bayer ups dividend ahead of annual results Feb 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)